178 related articles for article (PubMed ID: 10371752)
1. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
Conte A; Pizá P; García-Raja A; Grases F; Costa-Bauzá A; Prieto RM
Arch Esp Urol; 1999 Apr; 52(3):305-10. PubMed ID: 10371752
[TBL] [Abstract][Full Text] [Related]
2. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
Conte A; Pizá P; García-Raja A
Arch Esp Urol; 1999; 52(1):94-9. PubMed ID: 10101897
[TBL] [Abstract][Full Text] [Related]
3. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy.
Pak CY; Sakhaee K; Fuller CJ
Trans Assoc Am Physicians; 1983; 96():294-305. PubMed ID: 6679957
[TBL] [Abstract][Full Text] [Related]
4. Alkaline citrate in prevention of recurrent calcium oxalate stones.
Berg C
Scand J Urol Nephrol Suppl; 1990; 130():1-83. PubMed ID: 2291093
[TBL] [Abstract][Full Text] [Related]
5. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients.
Jaipakdee S; Prasongwatana V; Premgamone A; Reungjui S; Tosukhowong P; Tungsanga K; Suwantrai S; Noppawinyoowong C; Maskasame S; Sriboonlue P
J Med Assoc Thai; 2004 Mar; 87(3):255-63. PubMed ID: 15117041
[TBL] [Abstract][Full Text] [Related]
6. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest.
Zerwekh JE; Odvina CV; Wuermser LA; Pak CY
J Urol; 2007 Jun; 177(6):2179-84. PubMed ID: 17509313
[TBL] [Abstract][Full Text] [Related]
7. Urine citrate and renal stone disease.
Goldberg H; Grass L; Vogl R; Rapoport A; Oreopoulos DG
CMAJ; 1989 Aug; 141(3):217-21. PubMed ID: 2665909
[TBL] [Abstract][Full Text] [Related]
8. Effects of citrate on the different phases of calcium oxalate crystallization.
Tiselius HG; Berg C; Fornander AM; Nilsson MA
Scanning Microsc; 1993 Mar; 7(1):381-9; discussion 389-90. PubMed ID: 8316807
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of oxalocalcic lithiasis: effects of their interactions on calcium oxalate crystallization.
Muñoz JA; López-Mesas M; Valiente M
Urology; 2012 Nov; 80(5):1163.e13-8. PubMed ID: 22748613
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate.
Pak CY; Peterson R
Arch Intern Med; 1986 May; 146(5):863-7. PubMed ID: 3963975
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting calcium oxalate dihydrate fragmented calculi regrowth.
Costa-Bauzá A; Perelló J; Isern B; Sanchis P; Grases F
BMC Urol; 2006 Jul; 6():16. PubMed ID: 16822299
[TBL] [Abstract][Full Text] [Related]
12. Body size and 24-hour urine composition.
Taylor EN; Curhan GC
Am J Kidney Dis; 2006 Dec; 48(6):905-15. PubMed ID: 17162145
[TBL] [Abstract][Full Text] [Related]
13. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
Stoller ML; Chi T; Eisner BH; Shami G; Gentle DL
J Urol; 2009 Mar; 181(3):1140-4. PubMed ID: 19152919
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting the regrowth of renal stones in vitro: a contribution to the understanding of renal stone development.
Costa-Bauzá A; Isern B; Perelló J; Sanchis P; Grases F
Scand J Urol Nephrol; 2005; 39(3):194-9. PubMed ID: 16118089
[TBL] [Abstract][Full Text] [Related]
15. Phytate (IP6) is a powerful agent for preventing calcifications in biological fluids: usefulness in renal lithiasis treatment.
Grases F; Costa-Bauzá A
Anticancer Res; 1999; 19(5A):3717-22. PubMed ID: 10625946
[TBL] [Abstract][Full Text] [Related]
16. [Influence of urinary citrate levels on spontaneous calcium oxalate dihydrate crystalluria].
Hassani MA; Hennequin C; Lacour B; Daudon M
Prog Urol; 2005 Sep; 15(4):650-5. PubMed ID: 16459680
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent calcium oxalate stone patients.
Siener R; Schade N; Nicolay C; von Unruh GE; Hesse A
J Urol; 2005 May; 173(5):1601-5. PubMed ID: 15821507
[TBL] [Abstract][Full Text] [Related]
18. [The significance of citrate excretion and calcium/citrate quotients in urine in patients with calcium calculi].
Hofbauer J; Höbarth K; Zechner O
Z Urol Nephrol; 1990 Nov; 83(11):597-602. PubMed ID: 2100085
[TBL] [Abstract][Full Text] [Related]
19. Causes of hypocitraturia in recurrent calcium stone formers: focusing on urinary potassium excretion.
Domrongkitchaiporn S; Stitchantrakul W; Kochakarn W
Am J Kidney Dis; 2006 Oct; 48(4):546-54. PubMed ID: 16997050
[TBL] [Abstract][Full Text] [Related]
20. [Monitoring of the treatment of calcium-oxalate stone formers with the Bonn-Risk-Index].
Laube N; Schmidt M; Hesse A
Urologe A; 2003 Feb; 42(2):243-9. PubMed ID: 12607094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
